Category: Reading
BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+/HER2- breast cancer.
Reading
BGB-43395-101 (NCT06120283) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of BGB-43395, a selective CDK4 inhibitor, as monotherapy and in combination with fulvestrant, letrozole, or elacestrant in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer and other advanced solid tumors.
Reading
RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Reading
RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 study of tislelizumab combined with platinum and fluoropyrimidine chemotherapy compared to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Reading
